A Review of the Cytokine IL-17 in Ocular Surface and Corneal Disease

References

• Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Organ. 2001;79:214–21.
   PubMed Web of Science ®Google Scholar
• Whitcher JP, Srinivasan M, Upadhyay MP. Prevention of corneal ulceration in the developing world. Int Ophthalmol Clin. 2002;42:71–77.
   PubMedGoogle Scholar
• Forster RK. The management of infectious keratitis as we approach the 21st century. CLAO J. 1998;24:175–80.
   PubMedGoogle Scholar
• Carnt N, Stapleton F. Strategies for the prevention of contact lens-related Acanthamoeba keratitis: a review. Ophthalmic Physiol Opt. 2016;36(2):77–92. doi:10.1111/opo.12271.
   PubMed Web of Science ®Google Scholar
• Kaye S, Choudhary A. Herpes simplex keratitis. Prog Retin Eye Res. 2006;25(4):355–80. doi:10.1016/j.preteyeres.2006.05.001.
   PubMed Web of Science ®Google Scholar
• Agrawal V, Biswas J, Madhavan HN, Mangat G, Reddy MK, Saini JS, Sharma S, Srinivasan M. Current perspectives in infectious keratitis. Indian J of Ophthal. 1994;42:171–92.
   PubMedGoogle Scholar
• Hazlett L, Suvas S, McClellan S, Ekanayaka S. Challenges of corneal infections. Expert Rev Ophthal. 2016;11(4):285–97. doi:10.1080/17469899.2016.1203254.
   PubMed Web of Science ®Google Scholar
• Matsuzaki G, Umemura M. Interleukin-17 as an effector molecule of innate and acquired immunity against infections. Microbiol Immunol. 2007;51:1139–47.
   PubMed Web of Science ®Google Scholar
• Suryawanshi A, Mulik S, Sharma S, Reddy PB, Sehrawat S, Rouse BT. Ocular neovascularization caused by herpes simplex virus type 1 infection results from breakdown of binding between vascular endothelial growth factor A and its soluble receptor. J Immunol. 2011;186(6):3653–65. doi:10.4049/jimmunol.1003239.
   PubMed Web of Science ®Google Scholar
• Rajasagi NK, Reddy PB, Suryawanshi A, Mulik S, Gjorstrup P, Rouse BT. Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1. J Immunol. 2011;186(3):1735–46. doi:10.4049/jimmunol.1003456.
   PubMed Web of Science ®Google Scholar
• Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y, Fujikado N, Tanahashi Y, Akitsu A, Kotaki H, et al. Differential roles of interleukin-17A and-17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity. 2009;30(1):108–19. doi:10.1016/j.immuni.2008.11.009.
   PubMed Web of Science ®Google Scholar
• Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect. 2013;2(9):e60. doi:10.1038/emi.2013.58.
   PubMed Web of Science ®Google Scholar
• Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine. 2000;12(7):1092–99. doi:10.1006/cyto.2000.0681.
   PubMed Web of Science ®Google Scholar
• Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokine. J Exp Med. 1996;183(6):2593–603.
   PubMed Web of Science ®Google Scholar
• Jovanovic DV, Martel‐Pelletier J, Di Battista JA, Mineau F, Jolicoeur FC, Benderdour M, Pelletier JP. Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin‐17 in human monocyte/macrophages: a possible role in rheumatoid arthritis. Arthritis Rheum. 2000;43(5):1134–44. doi:10.1002/1529-0131(200005)43:5<1134::AID-ANR24>3.0.CO;2-#.
   PubMed Web of Science ®Google Scholar
• Koenders MI, Kolls JK, Oppers-Walgreen B, Van Den Bersselaar L, Joosten LA, Schurr JR, Schwarzenberger P, Van Den Berg WB, Lubberts E. Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall–induced arthritis. Arthritis Rheum. 2005;52(10):3239–47. doi:10.1002/art.21342.
   PubMed Web of Science ®Google Scholar
• Yeh S, Song XJ, Farley W, Li DQ, Stern ME, Pflugfelder SC. Apoptosis of ocular surface cells in experimentally induced dry eye. Invest Ophthalmol Vis Sci. 2003;44:124–29.
   PubMed Web of Science ®Google Scholar
• Luo L, Li DQ, Pflugfelder SC. Hyperosmolarity-induced apoptosis in human corneal epithelial cells is mediated by cytochrome c and MAPK pathways. Cornea. 2007;26(4):452–60. doi:10.1097/ICO.0b013e318030d259.
   PubMed Web of Science ®Google Scholar
• Ho AW, Gaffen SL. IL-17RC: a partner in IL-17 signaling and beyond. Semin Immunopathol. 2010;32(1):33–42. doi:10.1007/s00281-009-0185-0.
   PubMed Web of Science ®Google Scholar
• Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol. 2007;19(6):362–71. doi:10.1016/j.smim.2007.10.007.
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011;34(2):149–62. doi:10.1016/j.immuni.2011.02.012.
   PubMed Web of Science ®Google Scholar
• Taylor PR, Roy S, Sm L Jr, Sun Y, Howell SJ, Cobb BA, Li X, Autocrine PE. IL-17A–IL-17RC neutrophil activation in fungal infections is regulated by IL-6, IL-23, RORγt and Dectin-2. Nat Immunol. 2014;15(2):143–51. doi:10.1038/ni.2797.
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485–517. doi:10.1146/annurev.immunol.021908.132710.
   PubMed Web of Science ®Google Scholar
• Hernández-Santos N, Gaffen SL. Th17 cells in immunity to Candida albicans. Cell Host Microbe. 2012;11(5):425–35. doi:10.1016/j.chom.2012.04.008.
   PubMed Web of Science ®Google Scholar
• Liu J, Feng Y, Yang K, Li Q, Ye L, Han L, Wan H. Early production of IL-17 protects against acute pulmonary Pseudomonas aeruginosa infection in mice. FEMS Immunol Med Microbiol. 2011;61(2):179–88. doi:10.1111/j.1574-695X.2010.00764.x.
   PubMedGoogle Scholar
• Miyazaki Y, Hamano S, Wang S, Shimanoe Y, Iwakura Y, Yoshida H. IL-17 is necessary for host protection against acute-phase Trypanosoma cruzi infection. J Immunol. 2010;185(2):1150–57. doi:10.4049/jimmunol.0900047.
   PubMed Web of Science ®Google Scholar
• O’Connor W Jr, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, Kolls JK, Flavell RA. A protective function for interleukin 17A in T cell–mediated intestinal inflammation. Nat Immunol. 2009;10(6):603–09. doi:10.1038/ni.1736.
   PubMed Web of Science ®Google Scholar
• Huang X, Sun M, Chen F, Xiao Y, Chen L, Yao S, Cong Y. IL-17 promotes intestinal IgA response to intestinal infection but does not affect memory B cell development. J Immunol. 2017;198:200–16.
   Web of Science ®Google Scholar
• Eliçabe RJ, Silva JE, Dave MN, Lacoste MG, Tamashiro H, Blas R, Munarriz A, Rabinovich GA, Di Genaro MS. Association between IL-17 and IgA in the joints of patients with inflammatory arthropathies. BMC Immunol. 2017;18:8. doi:10.1186/s12865-017-0189-9.
   PubMed Web of Science ®Google Scholar
• Stapleton F, Carnt N. Contact lens-related microbial keratitis: how have epidemiology and genetics helped us with pathogenesis and prophylaxis. Eye. 2012;26(2):185–93. doi:10.1038/eye.2011.288.
   PubMed Web of Science ®Google Scholar
• Orlans HO, Hornby SJ, Bowler ICJW. In vitro antibiotic susceptibility patterns of bacterial keratitis isolates in Oxford, UK: a 10-year review. Eye. 2011;25(4):489–93. doi:10.1038/eye.2010.231.
   PubMed Web of Science ®Google Scholar
• Stapleton F, Keay LJ, Sanfilippo PG, Katiyar S, Edwards KP, Naduvilath T. Relationship between climate, disease severity, and causative organism for contact lens–associated microbial keratitis in Australia. Am J Ophthalmol. 2007;144(5):690–98. doi:10.1016/j.ajo.2007.06.037.
   PubMed Web of Science ®Google Scholar
• Bouhenni R, Dunmire J, Rowe T, Bates J. Proteomics in the study of bacterial keratitis. Proteomes. 2015;3(4):496–511. doi:10.3390/proteomes3040496.
   PubMed Web of Science ®Google Scholar
• Heimer SR, Yamada A, Russell H, Gilmore M. Response of corneal epithelial cells to Staphylococcus aureus. Virulence. 2010;1(4):223–35. doi:10.4161/viru.1.4.11466.
   PubMed Web of Science ®Google Scholar
• Zaidi TS, Zaidi T, Pier GB, Priebe GP. Topical neutralization of interleukin-17 during experimental Pseudomonas aeruginosa corneal infection promotes bacterial clearance and reduces pathology. Infect Immun. 2012;80(10):3706–12. doi:10.1128/IAI.00249-12.
   PubMed Web of Science ®Google Scholar
• Jurkunas U, Behlau I, Colby K. Fungal keratitis: changing pathogens and risk factors. Cornea. 2009;28(6):638–43. doi:10.1097/ICO.0b013e318191695b.
   PubMed Web of Science ®Google Scholar
• Thomas PA, Kaliamurthy J. Mycotic keratitis: epidemiology, diagnosis and management. Clin Microbiol Infect. 2013;19(3):210–20. doi:10.1111/1469-0691.12126.
   PubMed Web of Science ®Google Scholar
• Gaujoux T, Chatel MA, Chaumeil C, Laroche L, Borderie VM. Outbreak of contact lens-related Fusarium keratitis in France. Cornea. 2008;27(9):1018–21. doi:10.1097/ICO.0b013e318173144d.
   PubMed Web of Science ®Google Scholar
• Chang DC, Grant GB, O’Donnell K, Wannemuehler KA, Noble-Wang J, Rao CY, Jacobson LM, Crowell CS, Sneed RS, Lewis FM, et al. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA. 2006;296(8):953–63. doi:10.1001/jama.296.8.953.
   PubMed Web of Science ®Google Scholar
• Kisand K, Wolff ASB, Podkrajšek KT, Tserel L, Link M, Kisand KV, Ersvaer E, Perheentupa J, Erichsen MM, Bratanic N, et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med. 2010;207(2):299–308. doi:10.1084/jem.20091669.
   PubMed Web of Science ®Google Scholar
• Puel A, Döffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, Picard C, Cobat A, Ouachée-Chardin M, Toulon A, Bustamante J, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med. 2010;207(2):291–97. doi:10.1084/jem.20091983.
   PubMed Web of Science ®Google Scholar
• de Beaucoudrey L, Puel A, Filipe-Santos O, Cobat A, Ghandil P, Chrabieh M, Feinberg J, von Bernuth H, Samarina A, Jannière L, et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17–producing T cells. J Exp Med. 2008;205(7):1543–50. doi:10.1084/jem.20080321.
   PubMed Web of Science ®Google Scholar
• Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, Grimbacher B, Fulcher DA, Tangye SG, Cook MC. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med. 2008;205(7):1551–57. doi:10.1084/jem.20080218.
   PubMed Web of Science ®Google Scholar
• Taylor PR, Leal SM, Sun Y, Aspergillus PE. and Fusarium corneal infections are regulated by Th17 cells and IL-17-producing neutrophils. J Immunol. 2014;192(7):3319–27. doi:10.4049/jimmunol.1302235.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li H, Li Y, Zou Y, Dong X, Song W, Jia C, Li S, Xi H, Liu D, et al. IL‐17 plays a central role in initiating experimental Candida albicans infection in mouse corneas. Eur J Immunol. 2013;43(10):2671–82. doi:10.1002/eji.201242891.
   PubMed Web of Science ®Google Scholar
• Karthikeyan RS, Vareechon C, Prajna NV, Dharmalingam K, Pearlman E, Lalitha P. IL-17 expression in peripheral blood neutrophils from fungal keratitis patients and healthy cohorts in south India. J Infect Dis. 2015;211(1):130–34. doi:10.1093/infdis/jiu381.
   PubMed Web of Science ®Google Scholar
• Taylor PR, Roy S, Meszaros EC, Sun Y, Howell SJ, Malemud CJ, Pearlman E. JAK/STAT regulation of Aspergillus fumigatus corneal infections and IL-6/23-stimulated neutrophil, IL-17, elastase, and MMP9 activity. J Leukoc Biol. 2016;100(1):213–22. doi:10.1189/jlb.4A1015-483R.
   PubMed Web of Science ®Google Scholar
• Hodge WG, Seiff SR, Margolis TP. Ocular opportunistic infection incidences among patients who are HIV positive compared to patients who are HIV negative. Ophthalmology. 1998;105(5):895–900. doi:10.1016/S0161-6420(98)95033-3.
   PubMed Web of Science ®Google Scholar
• Young RC, Hodge DO, Liesegang TJ, Baratz KH. Incidence, recurrence, and outcomes of herpes simplex virus eye disease in Olmsted County, Minnesota, 1976-2007: the effect of oral antiviral prophylaxis. Arch Ophthalmol. 2010;128(9):1178–83. doi:10.1001/archophthalmol.2010.187.
   PubMedGoogle Scholar
• Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea. 2001;20:1–13.
   PubMed Web of Science ®Google Scholar
• Holland EJ, Schwartz GS. Classification of herpes simplex virus keratitis. Cornea. 1999;18:144–54.
   PubMed Web of Science ®Google Scholar
• Maertzdorf J, Osterhaus AD, Verjans GM. IL-17 expression in human herpetic stromal keratitis: modulatory effects on chemokine production by corneal fibroblasts. J Immunol. 2002;169:5897–903.
   PubMed Web of Science ®Google Scholar
• Molesworth-Kenyon SJ, Yin R, Oakes JE, Lausch RN. IL-17 receptor signaling influences virus-induced corneal inflammation. J Leukoc Biol. 2008;83(2):401–08. doi:10.1189/jlb.0807571.
   PubMed Web of Science ®Google Scholar
• Suryawanshi A, Veiga-Parga T, Rajasagi NK, Reddy PBJ, Sehrawat S, Sharma S, Rouse BT. Role of IL-17 and Th17 cells in herpes simplex virus-induced corneal immunopathology. J Immunol. 2011;187(4):1919–30. doi:10.4049/jimmunol.1100736.
   PubMed Web of Science ®Google Scholar
• Suryawanshi A, Veiga-Parga T, Reddy PB, Rajasagi NK, Rouse BT. IL-17A differentially regulates corneal vascular endothelial growth factor (VEGF)-A and soluble VEGF receptor 1 expression and promotes corneal angiogenesis after herpes simplex virus infection. J Immunol. 2012;188(7):3434–46. doi:10.4049/jimmunol.1102602.
   PubMed Web of Science ®Google Scholar
• Lorenzo-Morales J, Martín-Navarro CM, López-Arencibia A, Arnalich-Montiel F, Piñero JE, Valladares B. Acanthamoeba keratitis: an emerging disease gathering importance worldwide? Trends Parasitol. 2013;29(4):181–87. doi:10.1016/j.pt.2013.01.006.
   PubMed Web of Science ®Google Scholar
• Panjwani N. Pathogenesis of acanthamoeba keratitis. Ocul Surf. 2010;8:70–79.
   PubMed Web of Science ®Google Scholar
• Cohen EJ, Fulton JC, Hoffman CJ, Rapuano CJ, Laibson PR. Trends in contact lens-associated corneal ulcers. Cornea. 1996;15:566–70.
   PubMed Web of Science ®Google Scholar
• Sharma S, Garg P, Rao GN. Patient characteristics, diagnosis, and treatment of non-contact lens related acanthamoeba keratitis. Br J Ophthalmol. 2000;84:1103–08.
   PubMed Web of Science ®Google Scholar
• Suryawanshi A, Cao Z, Sampson JF, Panjwani N. IL-17A–mediated protection against acanthamoeba keratitis. J Immunol. 2015;194(2):650–63. doi:10.4049/jimmunol.1302707.
   PubMed Web of Science ®Google Scholar
• Carnt N, Montanez VM, Galatowicz G, Veli N, Calder V. Tear cytokine levels in contact lens wearers with acanthamoeba keratitis. Cornea. 2017;36(7):791–98. doi:10.1097/ICO.0000000000001238.
   PubMed Web of Science ®Google Scholar
• Moss SE, Klein R, Klein BE. Incidence of dry eye in an older population. Arch Ophthalmol. 2004;122(3):369–73. doi:10.1001/archopht.122.3.369.
   PubMed Web of Science ®Google Scholar
• Schein OD, Munoz B, Tielsch JM, Bandeen-Roche K, West S. Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997;124:723–28.
   PubMed Web of Science ®Google Scholar
• Bandeen-Roche K, Munoz B, Tielsch JM, West SK, Schein OD. Self-reported assessment of dry eye in a population-based setting. Invest Ophthalmol Vis Sci. 1997;38:2469–75.
   PubMed Web of Science ®Google Scholar
• De Paiva CS, Chotikavanich S, Pangelinan SB, Pitcher JD, Fang B, Zheng X, Ma P, Farley WJ, Siemasko KF, Niederkorn JY, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol. 2009;2(3):243–53. doi:10.1038/mi.2009.5.
   PubMed Web of Science ®Google Scholar
• Chauhan SK, El Annan J, Ecoiffier T, Goyal S, Zhang Q, Saban DR, Dana R. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol. 2009;182:1247–52.
   PubMed Web of Science ®Google Scholar
• Chauhan SK, Jin Y, Goyal S, Lee HS, Fuchsluger TA, Lee HK, Dana R. A novel pro-lymphangiogenic function for Th17/IL17. Blood. 2011;118:4630–34. doi:10.1182/blood-2011-01-332049.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chauhan SK, Lee HS, Saban DR, Dana R. Chronic dry eye disease is principally mediated by effector memory Th17 cells. Mucosal Immunol. 2014;7:38–45. doi:10.1038/mi.2013.20.
   PubMed Web of Science ®Google Scholar
• Lee SY, Han SJ, Nam SM, Yoon SC, Ahn JM, Kim TI, Kim EK, Seo KY. Analysis of tear cytokines and clinical correlations in Sjögren syndrome dry eye patients and non–sjögren syndrome dry eye patients. Am J Ophthal. 2013;156:247–53. doi:10.1016/j.ajo.2013.04.003.
   PubMed Web of Science ®Google Scholar
• Tan X, Sun S, Liu Y, Zhu T, Wang K, Ren T, Wu Z, Xu H, Zhu L. Analysis of Th17-associated cytokines in tears of patients with dry eye syndrome. Eye. 2014;28:608–13. doi:10.1038/eye.2014.38.
   PubMed Web of Science ®Google Scholar
• Liu R, Gao C, Chen H, Li Y, Jin Y, Qi H. Analysis of Th17-associated cytokines and clinical correlations in patients with dry eye disease. PloS one. 2017;12:e0173301. doi:10.1371/journal.pone.0173301.
   PubMed Web of Science ®Google Scholar
• Sadrai Z, Stevenson W, Okanobo A, Chen Y, Dohlman TH, Hua J, Amparo F, Chauhan SK, Dana R. PDE4 inhibition suppresses IL-17–associated immunity in dry eye disease. Invest Ophthal Vis Sci. 2012;53:3584–91. doi:10.1167/iovs.11-9110.
   PubMed Web of Science ®Google Scholar
• Subbarayal B, Chauhan SK, Di Zazzo A, Dana R. IL-17 augments B cell activation in ocular surface autoimmunity. J Immunol. 2016;197:3464–70. doi:10.4049/jimmunol.1502641.
   PubMed Web of Science ®Google Scholar
• Stern ME, Schaumburg CS, Dana R, Calonge M, Niederkorn JY, Pflugfelder SC. Autoimmunity at the ocular surface: pathogenesis and regulation. Mucosal Immunol. 2010;3:425–42. doi:10.1038/mi.2010.26.
   PubMed Web of Science ®Google Scholar
• Wright JF, Bennett F, Li B, Brooks J, Luxenberg DP, Whitters MJ, Tomkinson KN, Fitz LJ, Wolfman NM, Collins M, et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol. 2008;181(4):2799–805.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs. 2013;22(8):993–1005. doi:10.1517/13543784.2013.806483.
   PubMed Web of Science ®Google Scholar
• Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Durez P, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72–52ra72. doi:10.1126/scitranslmed.3001107.
   PubMed Web of Science ®Google Scholar
• Wei M, Duan D. Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials. Drug Des Devel Ther. 2016;10:2771–77. doi:10.2147/DDDT.S91374.
   PubMed Web of Science ®Google Scholar
• Wu D, Hou SY, Zhao S, Hou LX, Jiao T, Xu NN, Zhang N. Efficacy and safety of interleukin‐17 antagonists in patients with plaque psoriasis: a meta-analysis from phase 3 randomized controlled trials. J Eur Acad Dermatol Venereol. 2017;31(6):992–1003. doi:10.1111/jdv.14125.
   PubMed Web of Science ®Google Scholar
• Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewé R, Wordsworth P, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9906):1705–13. doi:10.1016/S0140-6736(13)61134-4.
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PDR, Wehkamp J, Feagan BG, Yao MD, Karczewski M, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–700. doi:10.1136/gutjnl-2011-301668.
   PubMed Web of Science ®Google Scholar
• Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, Lin S-L. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti–IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188(11):1294–302. doi:10.1164/rccm.201212-2318OC.
   PubMed Web of Science ®Google Scholar
• Hartung T, Daston G. Are in vitro tests suitable for regulatory use? Toxicol Sci. 2009;111(2):233–37. doi:10.1093/toxsci/kfp149.
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, Ortonne J-P, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EHZ, et al. Brodalumab, an anti–interleukin-17–receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–89. doi:10.1056/NEJMoa1109017.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, Sloan-Lancaster J. LY2439821, a humanized anti–interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010;62(4):929–39. doi:10.1002/art.27334.
   PubMed Web of Science ®Google Scholar